1 constitute a family of zinc enzymes that are capable of cleaving a wide range of extracellular matrix proteins and soluble and cell surface-associated regulatory proteins (1). MT1-MMP, a prototypic member of a membrane-anchored MMP subfamily, is distinguished from soluble MMPs by the existence of a C-terminal transmembrane domain that associates the protease with the lipid membrane bilayer and a cytoplasmic tail that interacts with the intracellular milieu (2). Currently, six membrane-type MMPs are known: MT1-, MT2-, MT3-, MT4-, MT5-and MT6-MMP (1). In contrast to the soluble MMPs, MT1-MMP is ideally positioned for regulating pericellular proteolysis (3, 4). Our prior studies and the results of other investigations have revealed a key role for MT1-MMP in carcinogenesis and malignancy and demonstrated that MT1-MMP is a likely centerpiece of malignant transformation and that MT1-MMP contributes directly to tumor cell migration, invasion, and metastasis (5-9). Proteolysis of matrix alone, however, does not fully explain the important and unique role of MT1-MMP in tumor growth and malignant progression and, in particular, in metastasis.
ber of a membrane-anchored MMP subfamily, is distinguished from soluble MMPs by the existence of a C-terminal transmembrane domain that associates the protease with the lipid membrane bilayer and a cytoplasmic tail that interacts with the intracellular milieu (2) . Currently, six membrane-type MMPs are known: MT1-, MT2-, MT3-, MT4-, MT5-and MT6-MMP (1) . In contrast to the soluble MMPs, MT1-MMP is ideally positioned for regulating pericellular proteolysis (3, 4) . Our prior studies and the results of other investigations have revealed a key role for MT1-MMP in carcinogenesis and malignancy and demonstrated that MT1-MMP is a likely centerpiece of malignant transformation and that MT1-MMP contributes directly to tumor cell migration, invasion, and metastasis (5) (6) (7) (8) (9) . Proteolysis of matrix alone, however, does not fully explain the important and unique role of MT1-MMP in tumor growth and malignant progression and, in particular, in metastasis.
The complement system comprises ϳ26 proteins (10, 11) . The classical pathway of complement is activated when C1 (the first component of complement) binds to immune complexes, certain microbial antigens, or self-neoepitopes. C1 and the classical pathway of complement is thus an important component of both innate and adaptive immunity (12) (13) (14) . C1 is a multimolecular complex comprising C1q and the calcium-dependent tetramer C1r(2)-C1s (2) . C1q is a 460-kDa protein that serves as a recognition molecule (15) (16) (17) . The overall shape of C1q resembles a bouquet of flowers with six N-terminal collagen-like triple helix stalks and the C-terminal globular heterotrimeric "head" domains that comprise A, B, and C subunits (18, 19) . Upon binding to immunoglobulin-coated targets, C1q undergoes a conformational change that initiates a highly specific intramolecular proteolytic activation of the C1r(2)-C1s(2) tetramer. These events are followed by complement propagation, which includes the deposition of opsonins on the activating cell surface, the release of anaphylatoxins, and the formation of the terminal cytolytic membrane attack complex, which eventually leads to cell death (10, 12, 20) . Another important, but less well understood, function of C1q is the induction of cell-specific functional responses mediated by its binding to receptors present on endothelial cells, dendritic cells, platelets, monocytes, lymphocytes, and leukocytes (15, 21) . So far, a few putative C1q-binding receptors have been identified. These receptors, which are likely to mediate C1q functions, are calreticulin/ cC1q-R, CD35/CR1, gC1q-R/p33, and CD93/C1q-Rp, although there is some controversy with the latter (22) .
We found, in the in vitro and in the cell-based assays, that MT1-MMP, in either its proteolytically active or inactive form, efficiently binds C1q in in vitro and cell-based assays. The catalytic domain of MT1-MMP and the C1q globular domain are involved in these receptor/ligand-like associations. The specificity of the MT1-MMP/C1q interactions was confirmed by MT1-MMP mutagenesis and by the identification of the interaction-deficient mutants. The binding of C1q to MT1-MMP does not activate complement and does not affect the proteolytic or TIMP-2 binding properties of MT1-MMP. We infer from our findings that the MT1-MMP⅐C1q complexes, rather than the individual MT1-MMP molecules, are predominantly exposed on the surface of either normal or neoplastic cells in the bloodstream.
MATERIALS AND METHODS
Antibodies and Reagents-All reagents were purchased from Sigma, unless otherwise indicated. C1q, normal human serum, and C4-depleted guinea pig serum were purchased from Advanced Research Technologies (San Diego, CA). Human IgM was obtained from Jackson ImmunoResearch Laboratories (West Grove, PA). Rabbit antibody AB815 against the hinge region of MT1-MMP, HRP-conjugated goat anti-rabbit antibodies, the TMB/M and TMB/E substrates, and GM6001 (a broad range hydroxamate inhibitor of MMPs) were obtained from Chemicon (Temecula, CA). Rabbit anti-human C1q was procured from Cedarlane (Hornby, Ontario, Canada). The recombinant catalytic domain of human MT1-MMP (MT1-CAT) was expressed in Escherichia coli, purified from the inclusion bodies, refolded to restore its native conformation as previously described (23) , and used in our cleavage experiments. Soluble MT1-CAT from Pichia (but not the E. coli-derived refolded MT1-CAT) was used in the C1q binding studies. Rabbit antibody to the MT1-CAT was generated in our laboratory (24) . The TIMP-2-free MMP-2 proenzyme was purified from the MMP-2-overexpressing stably transfected fibrosarcoma HT1080 cells (25) . To avoid the undesirable effects of complement in our assays, only heat-inactivated, complement-free sera were used in our experiments, unless otherwise indicated.
Cell Lines-Human breast carcinoma MCF7 (American Type Culture Collection (ATCC), Manassas, Virginia) stably transfected with the empty pcDNA3-zeo vector (Invitrogen) (control zeo cells), and with the full-length wild-type MT1-MMP (MT-WT cells), were extensively characterized in our previous works (7, 26, 27) . Human fibrosarcoma HT1080 cells, which synthesize MT1-MMP naturally, were obtained from ATCC. Transfected cells were routinely grown in Dulbecco's modified Eagle's medium (Irvine Scientific, Irvine, CA) supplemented with 10% fetal bovine serum (Tissue Culture Biologicals, Tulare, CA) and 0.2 mg/ml zeocin.
Protein Modeling-The protein modeling of the C1q A, B, and C subunits was performed using Modeler software (version 6v2, University of California, San Francisco). The 2.1-Å structure of the murine AdipoQ (Protein Data Bank (PDB) accession number 1C28), an abundant serum protein and a close homologue of the complement protein C1q protein (28) , was used as a template for building the models of human C1q. The high similarity of fold of human C1q A, B, and C subunits and murine AdipoQ was identified using the fold and function assignment system (FFAS) (ffas.ljcrf.edu). The modeled structures of the C1q subunits were validated using ProCheck (European Bioinformatics Institute, Cambridge, UK). The topology of the sterically unfavorable amino acid side chains of each of the subunits was corrected using an exhaustive search method (29) . The recently published crystal structure of human C1q at 1.9 Å resolution (19) was highly similar to the predicted models (root mean square deviation value of 2.36 Å) and, therefore, validates our calculations and the results of our proteinprotein docking studies.
Protein-Protein Docking-Protein-protein docking of the C1q subunits and the catalytic domain (MT1-CAT) of MT1-MMP (PDB accession number 1BQQ) was performed using GRAMM (version 1.03, State University of New York at Stony Brook, NY). The docking parameters were: helix mode, grid step 1.7, repulsion 10, angle of rotation Ϫ10 0 . The energy score distribution for docking of each subunit of C1q with MT1-CAT was analyzed. The most plausible score distribution was identified for docking between the A subunit and MT1-CAT. The energy score of the top-scoring model of the A subunit⅐MT1-CAT complex was Ϫ532. Similar scores are characteristic of the strongly interacting proteins (30, 31) . For comparison, the energy score for the top-scoring model of the C subunit and MT1-CAT interactions was Ϫ440. The five most probable models of C1q⅐MT1-MMP have been analyzed and validated. The final model of the C1q⅐MT1-CAT complex was built using the Swiss PDB viewer. Hydrogen bonds between the MT1-CAT and C1q subunit were also computed using the Swiss PDB viewer.
Cell ) were each cloned into the pTNT plasmid (Promega, Madison, WI). The resulting recombinant pTNT plasmids were used as templates in the cell-free double transcription/translation system (Promega). Each transcription/translation reaction included 20 l of the TNT T7 Quick Master mix, 1 l of [ 35 S]Met (10 mCi/ml) (Amersham Biosciences, Piscataway, NJ) and 1 l of the respective recombinant pTNT plasmid (0.5 g/ml). The reactions were incubated for 90 min at 30°C. Aliquots were then withdrawn from each reaction, diluted 10-fold, and the 1-l samples of the diluted aliquots were each analyzed by SDS-PAGE, followed by radioautography.
In addition, the sequence of MT1-CAT was modified by converting the residues of the 133-136, 134 -136, 171-174, 171-176, and 223-225 peptide sequence regions into the alanine residues. Mutations were inserted by using the QuikChange system (Stratagene, San Diego, CA) and the oligonucleotide primers, which carry the required mutations. The following direct and reverse (respectively) mutagenic primers were used: Ala 133-136 mutant, 5Ј-CTGCATCCAGAATTACACCGCCGCGGC-GGCCGAGTATGCCACATACGAG-3Ј and 5Ј-CTCGTATGTGGCATAC-TCGGCCGCCGCGGCGGTGTAATTCTGGATGCAG-3Ј; Ala 134 -136 mutant, 5Ј-CATCCAGAATTACACCCCCGCGGCGGCCGAGTATGCCAC-ATACGAG-3Ј and 5Ј-CTCGTATGTGGCATACTCGGCCGCCGCGGG-GGTGTAATTCTGGATG-3Ј; Ala 171-174 mutant, 5Ј-GCCTACATCCGT-GAGGGCGCTGCGGCGGCGGCCGACATCATGATCTTC-3Ј and 5Ј-G-AAGATCATGATGTCGGCCGCCGCCGCAGCGCCCTCACGGGATG-TAGGC-3Ј; Ala 171-176 mutant, 5Ј-GCCTACATCCGTGAGGGCGCTGC-GGCGGCGGCCGCCATCATGATCTTCTTTGCC-3Ј and 5Ј-GGCAAA-GAAGATCATGATGGCGGCCGCCGCCGCAGCGCCCTCACGGATG-TAGGC-3Ј; and A 223-225 mutant, 5Ј-CTCTGCCGAGCCTTGGACTGCC-GCGGCTGAGGATCTGAATGGAAATG-3Ј and 5Ј-CATTTCCATTCAG-ATCCTCAGCCGCGGCAGTCCAAGGCTCGGCAGAG-3Ј; nucleotides shown underlined bold indicate the altered codons). Following mutagenesis, the MT1-CAT mutants were recloned into the pTNT plasmid, and their structure was confirmed by sequencing.
To evaluate the ability of the expressed constructs to bind with C1q, the wells of a 96-well plate were coated overnight at 4°C with C1q (1 g/ml) in 50 mM sodium carbonate buffer, pH 9.5. The wells were blocked with 1% BSA. Aliquots (4 l) of the transcription/translation reactions were mixed with PBS (100 l) containing 0.5 M NaCl and 5% Triton X-100/1% BSA, and the samples were allowed to bind the wells for 1 h at 37°C. After extensive washing, the bound proteins were solubilized in a 2ϫ SDS sample buffer and analyzed by SDS-PAGE, followed by radioautography.
Expression of the MT1-MMP Constructs in Yeast-The cloning, expression, and purification of the individual hemopexin domain (MT1-PEX) of MT1-MMP and the soluble C-end-truncated MT1-MMP, lacking both the transmembrane domain and the cytoplasmic tail (MT1-⌬TM/⌬CT), have been described in our previous publications (27, 32, 33) . The cDNA fragment coding for the Ala 21 -Gly 284 peptide sequence of the prodomain, followed by the catalytic domain of MT1-MMP, was cloned in the pPIC9 plasmid (Invitrogen) under the control of the alcohol oxidase promoter and the ␣-mating factor signal peptide. Following the transformation of Pichia pastoris GS115 spheroplasts with the recombinant plasmid, the clones were grown and selected according to the manufacturer's instructions (Invitrogen). The expression levels of the construct were ϳ2 mg/l in the most efficient clones, as assessed by Western blotting of the medium samples. To generate preparative amounts of MT1-CAT, the clones were grown for 48 h in 1 liter of BMGY medium (10 g/liter yeast extract, 20 g/liter bactopeptone, 100 mM potassium phosphate buffer, pH 6.0, 13.4 g/liter yeast nitrogen base, 0.4 mg/liter biotin, 1% glycerol) and then for 24 h in BMMY medium (200 ml) (10 g/liter yeast extract, 20 g/liter bactopeptone, 100 mM potassium phosphate buffer, pH 6.0, 13.4 g/liter yeast nitrogen base, 0.4 mg/liter biotin, 0.5% methanol). MT1-CAT was purified from the medium by ammonium sulfate precipitation (70% saturation) followed by fast protein liquid chromatography on a MonoQ HR 5/5 column (Amersham Biosciences) equilibrated with 20 mM Tris-HCl, pH 8.0. MT1-CAT was eluted from the column with a 0 -0.8 M NaCl gradient and detected in the eluted fractions by SDS-PAGE.
Immunoprecipitation of Cell-deposited C1q-Following the incubation of the cells (1 ϫ 10 6 cells/60-mm plate) for 5 h with C1q (5 g/ml), the cells were washed with PBS, surface biotinylated for 1 h at 4°C with sulfo-N-hydroxysuccinimide long chain biotin (0.1 mg/ml) (Pierce), and lysed in 50 mM N-octyl-␤-D-glucopyranoside (Amresco, Solon, OH) in PBS supplemented with 1 mM CaCl 2 , 1 mM MgCl 2 , and a protease inhibitor mixture (phenylmethylsulfonyl fluoride (1 mM) and aprotinin, pepstatin, and leupeptin (1 g/ml each)). The lysate samples were precleared with protein G-agarose beads (Calbiochem). The precleared aliquots (1 mg total protein each) were immunoprecipitated with the C1q antibody (1 g) and protein G-agarose beads. The precipitated material was analyzed by Western blotting with HRP-ExtrAvidin and a TMB/M substrate. Where indicated, GM6001 (50 M) was co-incubated with the cells for 24 h prior to analyses and then included in all incubation buffers to block the proteolysis of cellular MT1-MMP.
MT1-MMP Proteolysis C1q and ␣1-Antitrypsin (AAT)-C1q
and AAT (1 g each) were co-incubated with either MT1-CAT (15-50 ng) or MT1-MMP-⌬TM/⌬CT (100 ng) for 2 h at 37°C in 15 l of 50 mM HEPES, 10 mM CaCl 2 , 0.5 mM MgCl 2 , 50 m ZnCl 2 , 0.01% Brij-35, pH 6.8. The cleavage samples were analyzed by SDS-PAGE, followed by Coomassie staining.
C4 Consumption Assay-Normal human serum was 100-fold diluted with GVB (veronal(barbital)-buffered saline, pH 7.4 (145 mM NaCl/5 mM sodium veronal), containing 0.1% gelatin, 0.15 mM CaCl 2 , and 1 mM MgCl 2 ). Aliquots of the diluted serum (20 l) were incubated for 1 h at 37°C with equimolar amounts of human IgM (88 g), MT1-CAT (2.7 g), and BSA (5.4 mg) (each dissolved in PBS) or with PBS alone (total sample volume 40 l). The samples (6 l each) were next added to the mixture that included the antibody-sensitized sheep erythrocytes (50 l), C4-depleted guinea pig serum (10 l), and GVB (450 l). Following incubation for 1 h at 37°C, the remaining erythrocytes were removed by centrifugation, and the A 412 value of the supernatant was measured on a microplate reader. The efficiency of the observed hemolysis in the experimental samples was expressed as a percentage in comparison with the total hemolysis of the erythrocytes lysed in water.
RESULTS

Modeling of MT1-MMP Interactions with
C1q-Our previous studies suggested the existence of a link of MT1-MMP to the complement system and tumor immunity and demonstrated the ability of MT1-MMP to bind gC1q-R (p33), a protein that is capable of associating with C1q (24, 34) . To extend these observations, we tested whether MT1-MMP is capable of binding with C1q directly. First, we employed in silico modeling and protein-protein docking to determine a likely mode of the MT1-MMP/C1q interactions. According to our in silico studies, the catalytic domain of the MT1-MMP was capable of binding C1q, especially the A subunit. The top-scored MT1-MMP/C1q docking model (Fig. 1, top Fig. 1 , bottom panel. The active site of MT1-MMP appears distant from the putative C1q binding site, suggesting that C1q is not a target of MT1-MMP proteolysis and that C1q will not interfere with MT1-MMP activity. These predictions were confirmed experimentally in our studies described below.
Thus, in silico modeling suggested the likely mode of the MT1-MMP/C1q interactions and directed us to the sequence regions of MT1-MMP, where mutagenesis might affect the interactions between these two proteins. To corroborate these suggestions and to demonstrate, in an expedient manner, the capability of MT1-MMP to bind C1q, we employed a cell-free double transcription/translation system.
Synthesis of MMPs in the Cell-free System and C1q
Binding-To accomplish our studies, we expressed and purified the truncated soluble forms of MT1-MMP, including MT1-⌬TM/ ⌬CT, which lacks the trans-membrane domain and the cytoplasmic tail, the proMT1-CAT species that represents the prodomain followed by the catalytic domain, and finally, the individual hemopexin-like domain (MT1-PEX). In addition, we recloned, in the pTNT plasmid vector, the cDNA sequences that represented the unmodified individual catalytic domain of MT1-MMP (MT1-CAT) as well as the mutant MT1-CAT. In these mutants, the amino acid residues of the 133 . The structure of the MT1-MMP forms used in the current study is schematically shown in Fig. 2 .
The pTNT plasmids expressing the wild-type and the mutant MT1-CAT were used as templates to generate the respective recombinant proteins in the cell-free transcription/translation system. Each of the individual templates was efficiently transcribed and translated in vitro and generated comparable amounts of the 35 S-labeled MT1-CAT species of the expected size (Fig. 3A) . Aliquots of the synthesized material were next allowed to bind C1q coated on plastic. After the removal of the unbound material by extensive washing, the bound MT1-CAT was eluted and evaluated by SDS-PAGE followed by radioautography. All of the constructs, except the mutants Ala [171] [172] [173] [174] , Ala [171] [172] [173] [174] [175] [176] , and Ala [223] [224] [225] , were capable of binding with C1q (Fig. 3A) . Luciferase, a product of the Renilla luciferase gene cloned in the pTNT vector and used as a negative control in our experiments, did not associate C1q (data not shown). An excess of unlabeled MT1-CAT and C1q, when added to the binding reactions, blocked the association of 35 S-labeled MT1-CAT with C1q coated on plastic (data not shown). These findings agreed closely enough with our , and His 249 are dark blue. The MT1-MMP residues that are likely to be involved in the association with C1q are dark red, whereas the rest of the MT1-MMP molecule is red. C1q is green; the residues of C1q, which appears to be important for MT1-MMP binding, are dark green (top panel). Hydrogen bonds are shown as dotted lines. Close-up of the protein-protein interface is shown in the bottom panel. L1, L3, and L5 loops of MT1-MMP, and S6, S9, and S12 ␤-sheets of the C1q A subunit are labeled. The 171-176 peptide sequence of MT1-MMP, which we believe is important for C1 binding, was subjected to mutagenesis to support our in silico modeling.
in silico modeling findings to confirm that the catalytic domain of MT1-MMP is capable of direct interaction with C1q and that the sequence regions To elucidate whether MT1-MMP is the only member of the membrane-type metalloproteinase subfamily able to bind C1q, we also cloned, in pTNT plasmid, the cDNA sequences encoding for the catalytic domain of MT2-MMP (MT2-CAT), MT3-MMP (MT3-CAT), and MT4-MMP (MT4-CAT). The catalytic domains were synthesized in the cell-free system, and the ability of the synthesized constructs to bind C1q was evaluated (Fig. 3B ). These studies demonstrated the similar efficiency of MT1-CAT and MT2-CAT in C1q binding. The efficiency of MT4-CAT binding and, especially the MT3-CAT binding, was significantly lower. These results imply that at least several types of membrane-tethered MMPs, rather than MT1-MMP alone, are the likely receptors for C1q. The sequence alignment of MT1-, MT2-, MT3-, and MT4-CAT suggests that the presence of the Ala 175 -Asp 176 in the sequence of MT1-MMP, MT2-MMP, and MT4-MMP is important to their ability to bind C1q efficiently (Fig. 3C) . The high divergence of the 223-225 region of MT1- ), as well as the wild-type MT2-CAT, MT3-CAT, and MT4-CAT were each synthesized and biosynthetically labeled with [ 35 S]Met using the cell-free system. Aliquots of the reactions were evaluated by SDS-PAGE followed by radioautography (upper panels). Aliquots of the synthesized material were next allowed to bind C1q coated on plastic. After the removal of excess label, the bound material was solubilized and evaluated by SDS-PAGE followed by radioautography (bottom panels). 
MT1-MMP Efficiently Binds but Does Not Degrade
C1q-To extend the data obtained in the cell-free system, we expressed the truncated forms of MT1-MMP in the yeast P. pastoris. The secreted soluble MT1-CAT and MT1-⌬TM/⌬CT, as well as the individual hemopexin domain of MT1-MMP (MT1-PEX), were purified from the medium. Under our experimental conditions, MT1-MMP was autolytically activated (33) . This event led to the conversion of the synthesized proMT1-⌬TM/⌬CT and proMT1-CAT into the fully proteolytically active MT1-⌬TM/ ⌬CT and MT1-CAT, respectively. These recombinant forms of MT1-MMP were tested in the panel of the C1q binding assays.
We determined whether MT1-⌬TM/⌬CT and MT1-PEX coated on plastic are capable of binding C1q. Fig. 4A demonstrates that MT1-⌬TM/⌬CT associated C1q efficiently, whereas the insignificant binding capability of MT1-PEX was relatively close to that of BSA, which was used as a control in our binding experiments. Next, we determined, using an enzyme-linked immunosorbent-like assay, the concentration dependence of the MT1-CAT construct binding to C1q coated on plastic (Fig.  4B) . We showed that MT1-CAT efficiently and specifically bound C1q in these assays with the K D app value equal to ϳ4 Ϯ 1 nM. The K D app was calculated using the one site binding equation Y ϭ B max ϫ X/K D ϩ X, where B max is the maximal binding, and K D is the concentration of ligand required to reach half-maximum binding. In sharp contrast with MT1-MMP, MMP-2, even at the 100-fold higher concentrations, does not associate with C1q coated on plastic (data not shown).
In agreement with in silico modeling, a 30 M excess of TIMP-2 (a natural protein inhibitor that inactivates MMPs by binding in the active site of enzymes) (35) did not affect the efficiency of MT1-CAT association with C1q but fully blocked the catalytic activity of MT1-MMP. The cleavage of the AAT serpin by MT1-MMP was used to demonstrate the proteolytic activity of the construct (Fig. 4C) . AAT is highly sensitive to proteolysis by individual MMPs and is commonly used as a 5 g/ml) , comprising the catalytic and the hemopexin domain, and the individual MT1-PEX (0.25 g/ml) were coated for 16 h at 4°C on the wells of a 96-well plate. The wells were then blocked with 1% BSA. C1q (30 ng/ml) was allowed to bind the MT1-MMP species for 1 h at 37°C. After washing to remove excess C1q, the bound C1q was identified with a rabbit C1q antibody (1:1000 dilution), followed with HRP-conjugated goat anti-rabbit antibodies (1:5000 dilution) and a TMB/E substrate. B, the individual MT1-CAT binds C1q. C1q (1 g/ml) was coated for 16 h at 4°C on the wells of a 96-well plate. The wells were blocked with 1% BSA. The indicated amounts of MT1-MMP were allowed to bind for 1 h at 37°C C1q. After extensive washing, the bound MT1-MMP was identified with the rabbit antibody against MT1-CAT (1 g/ml) followed with HRP-conjugated goat anti-rabbit antibody (1:5000 dilution) and a TMB/E substrate. C, TIMP-2 does not affect MT1-CAT binding with C1q. Plastic was coated with C1q (1 g/ml) and then blocked with 1% BSA. MT1-CAT (0.1 g/ml) alone or a mixture of MT1-CAT (0.1 g/ml) and TIMP-2 (3 g/ml; 30-fold M excess) was allowed to bind C1q for 1 h at 37°C. After washing, bound MT1-MMP was identified by the rabbit antibody against MT1-CAT (1 g/ml) followed with HRP-conjugated goat anti-rabbit antibody (1:5000 dilution) and a TMB/E substrate. The wells coated with 1% BSA were used as a control. Inset, TIMP-2 fully inhibits MT1-CAT cleavage activity. AAT (400 ng) were cleaved for 2 h with MT1-CAT (10 ng) alone or with a mixture of MT1-CAT (10 ng) and TIMP-2 (300 ng; 30-fold M excess). The digest samples were analyzed by SDS-PAGE. OD, optical density.
protein target in the cleavage assays of MMP activity in vitro (27, 36, 37) .
To support these data further and to identify whether C1q is susceptible or resistant to MT1-MMP proteolysis, we co-incubated MT1-CAT with C1q at an extremely high enzyme:substrate ratio of 1:1 (Fig. 5) . We determined that C1q was highly resistant to MT1-MMP proteolysis. In contrast, AAT was efficiently cleaved by MT1-CAT at a significantly lower enzyme: substrate molar ratio. We also demonstrated that the inclusion of a 15 M excess of C1q in the AAT cleavage reactions did not affect the cleavage of the latter by the proteinase (Fig. 5 ). These observations fully support the results of the in silico modeling. We, therefore, deduce that C1q is a ligand of MT1-MMP, that C1q binds to the regions of the catalytic domain of MT1-MMP, which are distant from the protease active site, and that C1q is not a target of MT1-MMP proteolysis.
C1q Binds to Cellular MT1-MMP-To support the physiologic existence of the MT1-MMP/C1q interactions, we performed studies in a cell-based system, using breast carcinoma MCF7 cells deficient in MT1-MMP (zeo cells) and MCF7 cells overexpressing the wild-type protease (MT-WT cells) (27, 32) . To evaluate MT1-MMP, zeo and MT-WT cells were lysed, and lysate aliquots (20 g of total protein each) were analyzed by Western blotting with the MT1-MMP antibody AB815 (Fig.  6A) . No specific bands were detected by using control rabbit IgG (data not shown). No MT1-MMP was detected in the lysates of zeo cells. In agreement with our earlier observations (7, 26) , MT1-MMP was predominantly represented in MT-WT cells by the 39-and 42-kDa stable, catalytically inactive ectodomain forms, which lacked the catalytic domain. Co-incubation of MT-WT cells with a potent, broad range hydroxamate inhibitor GM6001 blocked the MT1-MMP activity and self-proteolysis and stabilized the full-length 60 -63-kDa enzyme-proenzyme forms of MT1-MMP (38, 39) .
To determine whether MT1-MMP interacts with external C1q, zeo and MT-WT cells were co-incubated for 5 h with C1q (5 g/ml). The cells were next washed and surface-labeled with biotin and then lysed. Biotin-labeled, cell-attached C1q was identified in cell lysates by immunoprecipitation with a C1q antibody followed by Western blotting with HRP-streptavidin. We found no binding of C1q to the MT-MMP-deficient zeo cells. Because, MT1-MMP is largely represented by its degraded forms in MT-WT cells and the level of the full-length enzyme is relatively low, these cells were inefficient in binding C1q. GM6001 promoted the accumulation of the full-length MT1-MMP in MT-WT cells and conferred on these cells the ability to efficiently associate with C1q (Fig. 6B) .
To confirm that the association of C1q with cellular MT1-MMP is not a result of the protease overexpression, we used fibrosarcoma HT1080 cells, which are capable of producing the proteinase naturally. It is well established that in cell culture conditions, HT1080 cells predominantly exhibit the full-length MT1-MMP species (35, 40, 41) . When HT1080 cells were used in the C1q association assay, they, in a manner similar to MT-WT cells co-incubated with GM6001, were capable of a strong association with C1q (Fig. 6B) . In agreement, C1q may substitute for the MT1-MMP antibodies in the measurements of cellular MT1-MMP by fluorescence-activated cell sorter analysis (data not shown).
MT1-MMP Does Not Activate Complement-To assess the potential role of the MT1-MMP⅐C1q complex formation on complement activation, we employed a routine C4 consumption assay (Fig. 7) . IgM, MT1-CAT, and BSA (negative control) were co-incubated with human serum, and reaction aliquots were withdrawn. The residual levels of C4 were measured by coincubating the reaction aliquots with sensitized erythrocytes and C4-depleted guinea pig serum. IgM binds C1q and is a potent activator of complement. As expected, incubation of test samples with IgM resulted in complement activation and C4 consumption. In contrast, neither MT1-CAT nor the negative controls BSA and PBS, had any effect on residual C4 levels. These data indicate that MT1-MMP, despite its ability to bind C1q, does not activate complement.
DISCUSSION
The multifunctional MT1-MMP enzyme plays a number of important roles in connection with malignant cells (5, 6) . There is a strong correlation between MT1-MMP expression and the tumorigenicity for many cancer cell types (1, 6, 28, 42) . In agreement, the recent work of many authors has demonstrated that MT1-MMP is a potent protease involved in the cleavage of the extracellular matrix, in the activation of several soluble MMPs, and in the processing of the cellular adhesion and signaling receptors, such as integrins, CD44, tissue trans-glutaminase, LRP, and gC1q-R (9, 26, 27, 34, (42) (43) (44) (45) .
Our current work supports and substantially extends these earlier studies and provides, for the first time, biochemical evidence regarding the non-proteolytic, but potentially important and physiologically relevant, function of MT1-MMP. Our data indicate that MT1-MMP, in either its catalytically active or latent form, is a potent and highly specific cell surfaceassociated receptor of C1q. Our results identify the temporal and causal link associating MT1-MMP with C1q and demonstrate the biochemical mechanism of these interactions. The association of MT1-MMP with C1q is characteristic of a receptor/ligand interaction rather than of an interaction between a protease and its cleavage target. C1q is resistant to MT1-MMP proteolysis, because the regions of MT1-MMP involved in C1q binding are spatially distant from the active site of the protease (46) . In agreement, excess C1q does not interfere with TIMP-2 binding to the active site of MT1-MMP nor does it affect the ability of tumor cells expressing MT1-MMP to activate soluble MMP-2 (data not shown). These features make the MT1-MMP associations with C1q distinct from those reported for MT6-MMP/neutrophil-specific leukolysin and clusterin. Clusterin, a major component of serum, forms an inhibitory complex with MT6-MMP and plays the role of a negative regulator of the activity of the protease produced by neutrophils (47) .
Our data indicate that MT1-MMP is a novel cell surface receptor of C1q that associates with the globular domains of C1q. In contrast to the other human C1q cell surface receptors that have been described, MT1-MMP binds to the globular head of C1q, thus leaving the collagen-like stalk region of C1q exposed for interaction with the aforementioned C1q receptors (21) . In fact, because of the abundance of C1q in serum, it is likely that the vast majority of MT1-MMP exposed on the surface of both normal and neoplastic cells in the bloodstream exists in a complex with C1q.
Our data indicate that, in a similar manner to MT1-MMP, several individual members of the MT-MMP subfamily bind C1q. The binding of membrane-tethered MMPs with C1q is likely to regulate the C1q concentrations in a tumor microenvironment and in the vicinity of malignant cells. These molecular events may be functionally relevant to the subsequent interactions of malignant cells bearing MT-MMPs with the host cells, such as platelets and leukocytes, which express calreticulin/cC1q-R and other types of C1q receptors, which interact with the collagen stalk of C1q (15, 16, 21, 48) . Similarly, these events may contribute to the adhesion of metastatic cells to the endothelium and facilitate their transendothelial migration.
Sequence alignment of the 171-176 region demonstrates distinct positioning of charged residues in soluble MMPs as compared with that in MT1-MMP. Accordingly, it is likely that soluble MMPs with similar catalytic domains to MT1-MMP (such as MMP-1, -2, -3, -8, and -13) as well as membraneanchored MT5-MMP and MT6-MMP are incapable of efficiently associating with C1q (Fig. 8) . Because the 223-225 sequence region of MMPs is highly divergent, no conclusion in terms of C1q binding can be drawn from the sequence alignment. According to our experimental data and in agreement with sequence analyses, it appears that MT1-MMP and MT2-MMP are most efficient in associating with C1q. It is highly unlikely, therefore, that soluble MMPs will affect the amount of C1q available for binding to these two individual MT-MMPs.
It is intriguing that, although MT1-MMP binds to the C1q globular domains, it does not activate complement. When C1q binds to fixed immunoglobulin Fc domains, it undergoes a conformational change that activates the associated C1r and C1s serine proteases that initiate the classical pathway of complement. Why the binding of C1q to MT1-MMP does not similarly induce a conformational change and activate complement is not known, but an interesting possibility is that, in this capacity, MT1-MMP can function as an inhibitor of the classical pathway of complement. We have shown previously that MT1-MMP can inhibit complement by cleaving C3 (49) , and the current findings suggest a possibility of the second complement inhibitory mechanism for this enzyme.
We believe that our studies have identified a novel and important mechanism that sheds additional light on the exceptional role that MT1-MMP plays in cells/tissues. Our findings warrant additional tumor xenografts studies in vivo in complement-deficient mice. These studies will help us determine the relative importance of the individual complement-associated functions of MT1-MMP in the total tumorigenic effect of the protease. FIG. 7 . C4 consumption assay. IgM and MT1-CAT and BSA and PBS (negative controls) were co-incubated with human serum to induce the activation of complement and consumption of C4. The residual levels of C4 were identified by co-incubating the reaction aliquots with sensitized erythrocytes and C4-depleted guinea pig serum and calculated by comparing the extension of the erythrocyte hemolysis in the experimental samples with fully hemolysed erythrocytes. The residual levels of C4 are expressed as a percentage relative to the untreated human serum control. 
